Dynamic alteration of gene expression induced by anticancer-agent exposure in gastric cancer cell lines

Oncology Reports

Volumn 21, Issue 2, 2009, Pages 451-459

  Takahashi, Tsunehiro ^a   Saikawa, Yoshiro ^a   Nakamura, Rieko ^a   Kumagai, Koshi ^a   Takeuchi, Hiroya ^a   Kubota, Tetsuro ^b   Kitagawa, Yuko ^a  

^a KEIO UNIVERSITY   (Japan)

^b KEIO UNIVERSITY HOSPITAL   (Japan)

Author keywords

5 fluorouracil; Cisplatin; Gastric cancer cell line; Low density array; Messenger RNA quantification

Indexed keywords

ANTINEOPLASTIC AGENT; CATENIN; CAVEOLIN 1; CISPLATIN; CYCLIN DEPENDENT KINASE 2; CYCLIN DEPENDENT KINASE 4; CYCLIN DEPENDENT KINASE 7; CYCLINE; DNA METHYLTRANSFERASE 1; DNA METHYLTRANSFERASE 3A; DNA METHYLTRANSFERASE 3B; DNA TOPOISOMERASE; FLUOROURACIL; GLUTATHIONE REDUCTASE; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; HEAT SHOCK PROTEIN 27; HISTONE DEACETYLASE 4; HYPOXIA INDUCIBLE FACTOR 1ALPHA; INTERLEUKIN 15; INTERLEUKIN 15 RECEPTOR ALPHA; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR BETA; INTERLEUKIN 2 RECEPTOR GAMMA; INTERLEUKIN 4; INTERLEUKIN 4 RECEPTOR; INTERLEUKIN 7; MUCIN 6; SOMATOMEDIN B; URACIL DNA GLYCOSIDASE;

ARTICLE; CANCER CELL CULTURE; CANCER RESISTANCE; CELL LINE; CELL STRAIN MKN 45; CELL STRAIN MKN 74; CELL STRAIN TMK 1; CONTROLLED STUDY; DRUG EXPOSURE; GENE EXPRESSION PROFILING; HUMAN; HUMAN CELL; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; STOMACH CANCER; STRAIN DIFFERENCE; UNINDEXED SEQUENCE; DRUG EFFECT; DRUG RESISTANCE; GENE EXPRESSION; GENETICS; IC 50; STOMACH TUMOR; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION; GENE EXPRESSION PROFILING; HUMANS; INHIBITORY CONCENTRATION 50; STOMACH NEOPLASMS;

EID: 62849108748     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or_00000244     Document Type: Article

References (34)

1. Kamangar F, Dores GM and Anderson WF: Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol 24: 2137-2150, 2006.
2. Sakuramoto S, Sasako M, Yamaguchi T, et al: Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med 357: 1810-1820, 2007.
3. Ohtsu A: Current status and future prospects of chemotherapy for metastatic gastric cancer: a review. Gastric Cancer 8: 95-102, 2005.
4. Schipper DL and Wagener DJT: Chemotherapy of gastric cancer. Anticancer drugs 7: 137-149, 1995.
5. Hu JK, Chen ZX, Zhou ZG, et al: Intravenous chemotherapy for resected gastric cancer. Meta-analysis of randomized controlled trials. World J Gastroenterol 8: 1023-1028, 2002.
6. Golub TR, Slonim DK, Tamayo P, et al: Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. Science 286: 531-537, 1999.
7. Ulrich CM, Robien K and McLeod HL: Cancer pharmacogenetics: polymorphisms, pathways and beyond. Nat Rev Cancer 12: 912-920, 2003.
8. Banerjee D, Mayer-Kuckuk P, Capiaux G, et al: Novel aspects of resistance to drugs targeted to dihydrofolate reductase and thymidylate synthase. Biochim Biophys Acta 1587: 164-173, 2002.
9. Gottesman MM: Mechanisms of cancer drug resistance. Annu Rev Med 53: 615-627, 2002.
10. Yatomi M, Takiguchi Y, Asaka-Amano Y, et al: Altered gene expression by Cisplatin in a human squamous cell lung carcinoma cell line. Anticancer Res 27: 3235-3244, 2007.
11. Park JS, Yoon SY, Kim JM, et al: Identification of novel genes associated with the response to 5-FU treatment in gastric cancer cell lines using a cDNA microarray. Cancer Lett 214: 19-33, 2004.
12. Yuan R, Fan S, Achary M, et al: Altered gene expression pattern in cultured human breast cancer cells treated with hepatocyte growth factor/ Scatter factor in the setting of DNA damage. Cancer Res 61: 8022-8031, 2001.
13. Wong N, Chan KY, Macgregor PF, et al: Transcriptional profiling identifies gene expression changes associated with IFN-α tolerance in hepatitis C-related hepatocellular carcinoma cells. Clin Cancer Res 11: 1319-1325, 2005.
14. Ranganathan P, Agrawal A, Bhushan R, et al: Expression profiling of genes regulated by TGF-beta: Differential regulation in normal and tumor cells. BMC Genomics 8: 98, 2007.
15. Rafferty M, Faller WJ, Moss C, et al: Real-time quantitative reverse transcriptase-polymerase chain reaction analysis of melanoma progression-associated genes. Anticancer Res 27: 1301-1307, 2007.
16. Lyng MB, Laenkholm AV, Pallisgaard N, et al: Intratumor genetic heterogeneity of breast carcinomas as determined by fine needle aspiration and TaqMan low density array. Cell Oncol 29: 361-372, 2007.
17. Mosmann T: Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 65: 55-63, 1983.
18. Shimoyama Y, Kubota T, Watanabe M, et al: Predictability of in vivo chemosensitivity by in vitro MTT assay with reference to the clonogenic assay. J Surg Oncol 41: 12-18, 1989.
19. Suto A, Kubota T, Shimoyama Y, et al: MTT assay with reference to the clinical effect of chemotherapy. J Surg Oncol 42: 28-32, 1989.
20. Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C (T)) method. Methods 25: 402-408, 2001.
21. Andrews PA: Mechanisms of acquired resistance to cisplatin. Cancer Treat Res 73: 217-248, 1994.
22. Gosland M, Lum B, Schimmelpfennig J, et al: Insights into mechanisms of cisplatin resistance and potential for its clinical reversal. Pharmacotherapy 16: 16-39, 1996.
23. Mann SC, Andrews PA and Howell SB: Comparison of lipid content, surface membrane fluidity, and temperature dependence of cis-diamminedichloroplatinum (II) accumulation in sensitive and resistant human ovarian carcinoma cells. Anticancer Res 8: 1211-1215, 1988.
24. Kubbies M, Goller B, Schetters B, et al: Glutathione restores normal cell activation and cell cycle progression in cis-platinum treated human lymphocytes. Br J Cancer 64: 843-849, 1991.
25. Kasahara K, Fujiwara Y, Nishio K, et al: Metallothionein content correlates with sensitivity of human small cell lung cancer cell lines to cisplatin. Cancer Res 51: 3237-3242, 1991.
26. Masuda H, Tanaka T, Matsuda H, et al: Increased removal of DNA-bound platinum in a human ovarian cancer cell line resistant to cis-diamminedichloroplatinum (II). Cancer Res 50: 1863-1866, 1990.
27. Macgregor PF and Squire JA: Application of microarrays to the analysis of gene expression in cancer. Clin Chem 48: 1170-1177, 2002.
28. Aschele C, Lonardi S and Monfardini S: Thymidylate synthase expression as a predictor of clinical response to fluoropyrimidine-based chemotherapy in advanced colorectal cancer. Cancer Treat Rev 28: 27-47, 2002.
29. Isshi K, Sakuyama T, Gen T, et al: Predicting 5-FU sensitivity using human colorectal cancer specimens: comparison of tumor dihydropyrimidine dehydrogenase and orotate phosphoribosyl transferase activities with in vitro chemosensitivity to 5-FU. Int J Clin Oncol 7: 335-342, 2002.
30. Scherf U, Ross DT, Waltham M, et al: A gene expression database for the molecular pharmacology of cancer. Nat Genet 24: 236-244, 2000.
31. Ieta K, Tanaka F, Haraguchi N, et al: Biological and genetic characteristics of tumor-initiating cells in colon cancer. Ann Surg Oncol 15: 638-648, 2008.
32. Zhou J, Wulfkuhle J, Zhang H, et al: Activation of the PTEN/mTOR/ STAT3 pathway in breast cancer stem-like cells is required for viability and maintenance. Proc Natl Acad Sci USA 104: 16158-16163, 2007.
33. Haraguchi N, Utsunomiya T, Inoue H, et al: Characterization of a side population of cancer cells from human gastrointestinal system. Stem Cells 24: 506-513, 2006.
34. Tsuneyoshi N, Sumi T, Onda H, et al: PRDM14 suppresses expression of differentiation marker genes in human embryonic stem cells: Biochem Biophys Res Commun 367: 899-905, 2008.